References
- Allen, B., & Harocopos, A. (2016). Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma. Journal of Substance Abuse Treatment, 70, 81–86. https://doi.org/https://doi.org/10.1016/j.jsat.2016.08.002
- Anstice, S., Strike, C. J., & Brands, B. (2009). Supervised methadone consumption: Client issues and stigma. Substance Use & Misuse, 44(6), 794–808. https://doi.org/https://doi.org/10.1080/10826080802483936
- Augoustinos, M., & Every, D. (2007). Contemporary racist discourse: taboos against racism and racist accusations. In W. Ann, M. W. Bernadette, & G. Cindy (Eds.), Language, discourse and social psychology (pp. 233–254). Palgrave Macmillan UK. https://doi.org/https://doi.org/10.1057/9780230206168_10
- Becker, G., & Arnold, R. (1986). Stigma as a social and cultural construct. In S. C. Ainlay, G. Becker, & L. M. Coleman (Eds.), The dilemma of difference: A multidisciplinary view of stigma (pp. 39–57). Springer US. https://doi.org/https://doi.org/10.1007/978-1-4684-7568-5_3
- Beetham, T., Saloner, B., Gaye, M., Wakeman, S. E., Frank, R. G., & Barnett, M. L. (2020). Therapies offered at residential addiction treatment programs in the United States. JAMA, 324(8), 804–806. https://doi.org/https://doi.org/10.1001/jama.2020.8969
- Boston Globe Editorial Board. (2020, May 24). Post-coronavirus pandemic, methadone should be just as easy to get. The Boston Globe. https://www.bostonglobe.com/2020/05/24/opinion/post-coronavirus-pandemic-keep-methadone-easy-obtain/
- Chaar, B. B., Wang, H., Day, C. A., Hanrahan, J. R., Winstock, A. R., & Fois, R. (2013). Factors influencing pharmacy services in opioid substitution treatment. Drug and Alcohol Review, 32(4), 426–434. https://doi.org/https://doi.org/10.1111/dar.12032
- Chandler, A., Whittaker, A., Cunningham-Burley, S., Williams, N., McGorm, K., & Mathews, G. (2013). Substance, structure and stigma: Parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods. The International Journal on Drug Policy, 24(6), e35–e42. https://doi.org/https://doi.org/10.1016/j.drugpo.2013.04.004
- Cioe, K., Biondi, B. E., Easly, R., Simard, A., Zheng, X., & Springer, S. A. (2020). A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119, 108146. https://doi.org/https://doi.org/10.1016/j.jsat.2020.108146
- Conner, K. O., & Rosen, D. (2008). You’re nothing but a Junkie”: Multiple experiences of stigma in an aging methadone maintenance population. Journal of Social Work Practice in the Addictions, 8(2), 244–264. https://doi.org/https://doi.org/10.1080/15332560802157065
- Cooper, S., & Nielsen, S. (2017). Stigma and social support in pharmaceutical opioid treatment populations: A scoping review. International Journal of Mental Health and Addiction, 15(2), 452–469. https://doi.org/https://doi.org/10.1007/s11469-016-9719-6
- DuPont, R. L., McLellan, A. T., Carr, G., Gendel, M., & Skipper, G. E. (2009). How are addicted physicians treated? A national survey of physician health programs. J Subst Abuse Treat, 37(1), 1–7. https://doi.org/https://doi.org/10.1016/j.jsat.2009.03.010
- Earnshaw, V., Smith, L., & Copenhaver, M. (2013). Drug addiction stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma. International Journal of Mental Health and Addiction, 11(1), 110–122. https://doi.org/https://doi.org/10.1007/s11469-012-9402-5
- Fischer, B. (2000). Prescriptions, power and politics: The turbulent history of methadone maintenance in Canada. Journal of Public Health Policy, 21(2), 187–210. JSTOR. https://doi.org/https://doi.org/10.2307/3343343
- Fogler, S. (2020, December 8). Stigma, weaponized in many forms, helps fuel the addiction crisis. STAT. https://www.statnews.com/2020/12/08/stigma-weaponized-helps-fuel-addiction-crisis/
- Friedmann, P. D., Wilson, D., Knudsen, H. K., Ducharme, L. J., Welsh, W. N., Frisman, L., Knight, K., Lin, H.-J., James, A., Albizu-Garcia, C. E., Pankow, J., Hall, E. A., Urbine, T. F., Abdel-Salam, S., Duvall, J. L., & Vocci, F. J. (2015). Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. Journal of Substance Abuse Treatment, 50, 50–58. https://doi.org/https://doi.org/10.1016/j.jsat.2014.10.001
- Gidman, W., & Coomber, R. (2014). Contested space in the pharmacy: Public attitudes to pharmacy harm reduction services in the West of Scotland . Research in Social & Administrative Pharmacy : RSAP, 10(3), 576–587. https://doi.org/https://doi.org/10.1016/j.sapharm.2013.07.006
- Ginter, W. (2012). Methadone anonymous and mutual support for medication-assisted recovery. Journal of Groups in Addiction & Recovery, 7(2-4), 189–201. https://doi.org/https://doi.org/10.1080/1556035X.2012.705699
- Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Prentice Hall.
- Gordon, A. J., Kavanagh, G., Krumm, M., Ramgopal, R., Paidisetty, S., Aghevli, M., Goodman, F., Trafton, J., & Liberto, J. (2011). Facilitators and barriers in implementing buprenorphine in the Veterans health administration. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors, 25(2), 215–224. https://doi.org/https://doi.org/10.1037/a0022776
- Guichard, A., Lert, F., Brodeur, J.-M., & Richard, L. (2007). Buprenorphine substitution treatment in France: Drug users’ views of the doctor-user relationship. Social Science & Medicine (1982), 64(12), 2578–2593. https://doi.org/https://doi.org/10.1016/j.socscimed.2007.02.049
- Hamza, H., & Bryson, E. O. (2012). Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: A hidden controversy. Mayo Clinic Proceedings, 87(3), 260–267. https://doi.org/https://doi.org/10.1016/j.mayocp.2011.09.007
- Harden, A. (2010). Mixed-methods systematic reviews: integrating quantitative and qualitative findings (Technical Brief No. 25; NCDDR: FOCUS). https://ktdrr.org/ktlibrary/articles_pubs/ncddrwork/focus/focus25/Focus25.pdf
- Harris, J., & McElrath, K. (2012). Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824. https://doi.org/https://doi.org/10.1177/1049732311432718
- Hatcher, A. E., Mendoza, S., & Hansen, H. (2018). At the Expense of a life: Race, class, and the meaning of buprenorphine in pharmaceuticalized “Care”. Substance Use & Misuse, 53(2), 301–310. https://doi.org/https://doi.org/10.1080/10826084.2017.1385633
- Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction (Abingdon, England), 113(7), 1188–1209. https://doi.org/https://doi.org/10.1111/add.14180
- Khatri, U., Davis, C. S., Krawczyk, N., Lynch, M., Berk, J., & Samuels, E. A. (2020, September 11). These key telehealth policy changes would improve buprenorphine access while advancing health equity | Health Affairs. Health Affairs Blog. https://doi.org/https://doi.org/10.1377/hblog20200910.498716
- Knudsen, H. K., Ducharme, L. J., Roman, P. M., & Link, T. (2005). Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment, 29(2), 95–106. https://doi.org/https://doi.org/10.1016/j.jsat.2005.05.002
- Krawczyk, N., Negron, T., Nieto, M., Agus, D., & Fingerhood, M. I. (2018). Overcoming medication stigma in peer recovery: A new paradigm. Substance Abuse, 39(4), 404–409. https://doi.org/https://doi.org/10.1080/08897077.2018.1439798
- Lancaster, K., Sutherland, R., & Ritter, A. (2014). Examining the opinions of people who use drugs towards drug policy in Australia. Drugs: Education, Prevention & Policy, 21(2), 93–101. https://doi.org/https://doi.org/10.3109/09687637.2013.838211
- Larney, S., Zador, D., Sindicich, N., & Dolan, K. (2017). A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug and Alcohol Review, 36(3), 305–310. https://doi.org/https://doi.org/10.1111/dar.12442
- Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A Cohort Study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/https://doi.org/10.7326/M17-3107
- Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., Peavy, K. M., Ross, S., Salazar, D., Schkolnik, P., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet, 391(10118), 309–318. https://doi.org/https://doi.org/10.1016/S0140-6736(17)32812-X https://doi.org/https://doi.org/10.1016/S0140-6736(17)32812-X
- Link, B. G., & Phelan, J. C. (2001). Conceptualizing stigma. Annual Review of Sociology, 27(1), 363–385. https://doi.org/https://doi.org/10.1146/annurev.soc.27.1.363
- Livingston, J. D., Adams, E., Jordan, M., MacMillan, Z., & Hering, R. (2018). Primary care physicians’ views about prescribing methadone to treat opioid use disorder. Substance Use & Misuse, 53(2), 344–353. https://doi.org/https://doi.org/10.1080/10826084.2017.1325376
- Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. Addiction (Abingdon, England), 107(1), 39–50. https://doi.org/https://doi.org/10.1111/j.1360-0443.2011.03601.x
- Lloyd, C. (2013). The stigmatization of problem drug users: A narrative literature review. Drugs: Education, Prevention & Policy, 20(2), 85–95. https://doi.org/https://doi.org/10.3109/09687637.2012.743506
- MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., Degenhardt, L., & Hickman, M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ, 345(3), e5945–e5945. https://doi.org/https://doi.org/10.1136/bmj.e5945
- Madden, E. F. (2019). Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Science & Medicine (1982), 232, 324–331. https://doi.org/https://doi.org/10.1016/j.socscimed.2019.05.027
- Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews, 3(3), CD002209. https://doi.org/https://doi.org/10.1002/14651858.CD002209.pub2[PMC][19588333
- Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. Feb 6;(2):CD002207. https://doi.org/https://doi.org/10.1002/14651858.CD002207.pub4. PMID: 24500948.
- Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L., & DuPont, R. L. (2016). Outcomes for physicians with opioid dependence treated without agonist pharmacotherapy in physician health programs. Journal of Substance Abuse Treatment, 64, 47–54. https://doi.org/https://doi.org/10.1016/j.jsat.2016.02.004
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, T. P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097https://doi.org/https://doi.org/10.1371/journal.pmed.1000097
- Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019). Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend, 200, 34–39. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.02.031
- National Institute on Drug Abuse (NIDA). (1999). NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. European Addiction Research, 5(1), 50–51. https://doi.org/https://doi.org/10.1159/000018963
- National Institutes of Health. (1997). The NIH consensus development program: effective medical treatment of opiate addiction [Consensus Development Conference Statement]. https://consensus.nih.gov/1997/1998treatopiateaddiction108html.htm
- Notley, C., Holland, R., Maskrey, V., Nagar, J., & Kouimtsidis, C. (2014). Regaining control: The patient experience of supervised compared with unsupervised consumption in opiate substitution treatment. Drug and Alcohol Review, 33(1), 64–70. https://doi.org/https://doi.org/10.1111/dar.12079
- O’Donnell, A., Addison, M., Spencer, L., Zurhold, H., Rosenkranz, M., McGovern, R., Gilvarry, E., Martens, M.-S., Verthein, U., & Kaner, E. (2019). Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature. Addiction (Abingdon, England), 114(1), 24–47. https://doi.org/https://doi.org/10.1111/add.14434
- Olsen, Y., & Sharfstein, J. M. (2014). Confronting the Stigma of Opioid Use disorder-and its treatment. JAMA, 311(14), 1393–1394. https://doi.org/https://doi.org/10.1001/jama.2014.2147
- Paquette, C. E., Syvertsen, J. L., & Pollini, R. A. (2018). Stigma at every turn: Health services experiences among people who inject drugs. The International Journal on Drug Policy, 57, 104–110. https://doi.org/https://doi.org/10.1016/j.drugpo.2018.04.004
- Pescosolido, B. A., & Martin, J. K. (2015). The stigma complex. Annual Review of Sociology, 41(1), 87–116. https://doi.org/https://doi.org/10.1146/annurev-soc-071312-145702
- Pescosolido, B. A., Medina, T. R., Martin, J. K., & Long, J. S. (2013). The “Backbone” of stigma: Identifying the global core of public prejudice associated with mental illness. American Journal of Public Health, 103(5), 853–860. https://doi.org/https://doi.org/10.2105/AJPH.2012.301147
- Peterson, J. A., Schwartz, R. P., Mitchell, S. G., Reisinger, H. S., Kelly, S. M., O’Grady, K. E., Brown, B. S., & Agar, M. H. (2010). Why don’t out-of-treatment individuals enter methadone treatment programmes?The International Journal on Drug Policy, 21(1), 36–42. https://doi.org/https://doi.org/10.1016/j.drugpo.2008.07.004
- Priest, K. C. (2020, April 3). The COVID-19 pandemic: Practice and policy considerations for patients with opioid use disorder | Health Affairs. Health Affairs Blog. https://doi.org/https://doi.org/10.1377/hblog20200331.557887
- Radcliffe, P., & Stevens, A. (2008). Are drug treatment services only for “‘thieving junkie scumbags’? Drug users and the management of stigmatised identities”? . Social Science & Medicine (1982), 67(7), 1065–1073. PsycINFO. https://doi.org/https://doi.org/10.1016/j.socscimed.2008.06.004
- Rieckmann, T. R., Abraham, A. J., Kovas, A. E., McFarland, B. H., & Roman, P. M. (2014). Impact of research network participation on the adoption of buprenorphine for substance abuse treatment. Addictive Behaviors, 39(5), 889–896. https://doi.org/https://doi.org/10.1016/j.addbeh.2014.01.016
- Rieckmann, T., Daley, M., Fuller, B. E., Thomas, C. P., & McCarty, D. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment, 32(2), 207–215. https://doi.org/https://doi.org/10.1016/j.jsat.2006.09.002
- Sanders, J. J., Roose, R. J., Lubrano, M. C., & Lucan, S. C. (2013). Meaning and methadone: Patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. Journal of Addiction Medicine, 7(5), 307–313. https://doi.org/https://doi.org/10.1097/ADM.0b013e318297021e
- Simmons-Duffin, S. (2019, September 6). For health workers struggling with addiction, why are treatment options limited? NPR.Org. https://www.npr.org/sections/health-shots/2019/09/06/757990241/for-health-workers-struggling-with-addiction-why-are-treatment-options-limited
- Smith, C. B. R. (2010). Socio-spatial stigmatization and the contested space of addiction treatment: Remapping strategies of opposition to the disorder of drugs. Social Science & Medicine (1982), 70(6), 859–866. https://doi.org/https://doi.org/10.1016/j.socscimed.2009.10.033
- Smye, V., Browne, A. J., Varcoe, C., & Josewski, V. (2011). Harm reduction, methadone maintenance treatment and the root causes of health and social inequities: An intersectional lens in the Canadian context. Harm Reduction Journal, 8, 17. PsycINFO. https://doi.org/https://doi.org/10.1186/1477-7517-8-17
- Sulzer, S. H., Prevedel, S., Barrett, T., Voss, M. W., Manning, C., & Madden, E. F. (2021). Professional education to reduce provider stigma toward harm reduction and pharmacotherapy. Drugs: Education, Prevention and Policy, 1–11. https://doi.org/https://doi.org/10.1080/09687637.2021.1936457
- The Critical Appraisals Skills Programme. (2018). CASP checklists. https://casp-uk.net/casp-tools-checklists/
- Thomas, J., & Harden, A. (2008). Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology, 8(1), 45. https://doi.org/https://doi.org/10.1186/1471-2288-8-45[PMC][18616818
- Uchtenhagen, A. (2013). Abstinence versus agonist maintenance treatment: An outdated debate?European Addiction Research, 19(6), 283–286. https://doi.org/https://doi.org/10.1159/000350373
- Wakeman, S. E. (2016). Using science to battle stigma in addressing the opioid epidemic: Opioid agonist therapy saves lives. The American Journal of Medicine, 129(5), 455–456. https://doi.org/https://doi.org/10.1016/j.amjmed.2015.12.028
- Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), e1920622. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2019.20622
- Wakeman, S. E., & Rich, J. D. (2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330–333. https://doi.org/https://doi.org/10.1080/10826084.2017.1363238
- Woo, J., Bhalerao, A., Bawor, M., Bhatt, M., Dennis, B., Mouravska, N., Zielinski, L., & Samaan, Z. (2017). "Don’t Judge a Book Its Cover": A Qualitative Study of Methadone Patients’ Experiences of Stigma”. Substance Abuse : Research and Treatment, 11, 1178221816685087https://doi.org/https://doi.org/10.1177/1178221816685087
- Woods, J. S., & Joseph, H. (2012). Reducing stigma through education to enhance medication-assisted recovery. Journal of Addictive Diseases, 31(3), 226–235. https://doi.org/https://doi.org/10.1080/10550887.2012.694599
- Yarborough, B. J. H., Stumbo, S. P., McCarty, D., Mertens, J., Weisner, C., & Green, C. A. (2016). Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug and Alcohol Dependence, 160, 112–118. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2015.12.031
- Zelenev, A., Shea, P., Mazhnaya, A., Rozanova, J., Madden, L., Marcus, R., & Altice, F. L. (2018). Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug and Alcohol Dependence, 190, 82–88. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.05.027